{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:21:12Z","timestamp":1788402072187,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2021\/05\/X\/NZ7\/00353"],"award-info":[{"award-number":["2021\/05\/X\/NZ7\/00353"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Saliva sampling is one of the methods of therapeutic drug monitoring for mycophenolic acid (MPA) and its metabolite, mycophenolic acid glucuronide (MPAG). The study describes the liquid chromatography tandem mass spectrometry (LC\u2013MS\/MS) method developed for saliva MPA and MPAG determination in children with nephrotic syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The mobile phase consisted of methanol and water at gradient flow, both with 0.1% formic acid. Firstly, 100\u00a0\u00b5L of saliva was evaporated at 45\u00a0\u00b0C for 2\u00a0h to dryness, secondly, it was reconstituted in the mobile phase, and finally 10\u00a0\u00b5L was injected into the LC\u2013MS\/MS system. Saliva from ten children with nephrotic syndrome treated with mycophenolate mofetil was collected with Salivette<jats:sup>\u00ae<\/jats:sup>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For MPA and MPAG, within the 2\u2013500\u00a0ng\/mL range, the method was selective, specific, accurate and precise within-run and between-run. No carry-over and matrix effects were observed. Stability tests showed that MPA and MPAG were stable in saliva samples if stored for 2\u00a0h at room temperature, 18\u00a0h at 4\u00a0\u00b0C, and at least 5\u00a0months at \u2212\u200980\u00a0\u00b0C as well as after three freeze\u2013thaw cycles, in a dry extract for 16\u00a0h at 4\u00a0\u00b0C, and for 8\u00a0h at 15\u00a0\u00b0C in the autosampler. The analytes were not adsorbed onto Salivette<jats:sup>\u00ae<\/jats:sup> cotton swabs. For concentrations above 500\u00a0ng\/mL, the samples may be diluted twofold. In children, saliva MPA and MPAG were within the ranges of 4.6\u2013531.8\u00a0ng\/mL and 10.7\u2013183.7\u00a0ng\/mL, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The evaluated LC\u2013MS\/MS method has met the validation requirements for saliva MPA and MPAG determination in children with nephrotic syndrome. Further studies are needed to explore plasma\u2013saliva correlations and assess their potential contribution to MPA monitoring.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s43440-024-00574-9","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T03:01:26Z","timestamp":1710471686000},"page":"600-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Liquid chromatography\u2013tandem mass spectrometry method for mycophenolic acid and its glucuronide determination in saliva samples from children with nephrotic syndrome"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-1575","authenticated-orcid":false,"given":"Joanna","family":"Sobiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matylda","family":"Resztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Zachwieja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Ostalska-Nowicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"574_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit. 2021;43:150\u2013200. https:\/\/doi.org\/10.1097\/FTD.0000000000000871.","journal-title":"Ther Drug Monit"},{"key":"574_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/17425255.2021.1843633","volume":"17","author":"R Ehren","year":"2021","unstructured":"Ehren R, Schijvens AM, Hackl A, Schreuder MF, Weber LT. Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion. Expert Opin Drug Metab Toxicol. 2021;17:201\u201313. https:\/\/doi.org\/10.1080\/17425255.2021.1843633.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"574_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/09546634.2019.1642996","volume":"31","author":"K Phan","year":"2020","unstructured":"Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatol Treat. 2020;31:810\u20134. https:\/\/doi.org\/10.1080\/09546634.2019.1642996.","journal-title":"J Dermatol Treat"},{"key":"574_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejps.2015.06.017","volume":"77","author":"J Sobiak","year":"2015","unstructured":"Sobiak J, Resztak M, Ostalska-Nowicka D, Zachwieja J, G\u0105siorowska K, Piechanowska W, et al. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci. 2015;77:189\u201396. https:\/\/doi.org\/10.1016\/j.ejps.2015.06.017.","journal-title":"Eur J Pharm Sci"},{"key":"574_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/FTD.0000000000000258","volume":"38","author":"\u00c1 Hackl","year":"2016","unstructured":"Hackl \u00c1, Cseprek\u00e1l O, Gessner M, Liebau MC, Habbig S, Ehren R, et al. Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: does therapeutic drug monitoring make a difference? Ther Drug Monit. 2016;38:274\u20139. https:\/\/doi.org\/10.1097\/FTD.0000000000000258.","journal-title":"Ther Drug Monit"},{"key":"574_CR6","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2215\/CJN.00320116","volume":"11","author":"S Tellier","year":"2016","unstructured":"Tellier S, Dallocchio A, Guigonis V, Saint-Marcoux F, Llanas B, Ichay L, et al. Mycophenolic acid pharmacokinetics and relapse in children with steroid-dependent idiopathic nephrotic syndrome. Clin J Am Soc Nephrol. 2016;11:1777\u201382. https:\/\/doi.org\/10.2215\/CJN.00320116.","journal-title":"Clin J Am Soc Nephrol"},{"key":"574_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/petr.12695","volume":"20","author":"LC Martial","year":"2016","unstructured":"Martial LC, Jacobs BAW, Cornelissen EAM, de Haan AF, Koch BC, Burger DM, et al. Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. Pediatr Transplant. 2016;20:492\u20139. https:\/\/doi.org\/10.1111\/petr.12695.","journal-title":"Pediatr Transplant"},{"key":"574_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/FTD.0000000000000363","volume":"39","author":"C Barau","year":"2017","unstructured":"Barau C, Mellos A, Chhun S, Lacaille F, Furlan V. Pharmacokinetics of mycophenolic acid and dose optimization in children after intestinal transplantation. Ther Drug Monit. 2017;39:37\u201342. https:\/\/doi.org\/10.1097\/FTD.0000000000000363.","journal-title":"Ther Drug Monit"},{"key":"574_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bcp.12392","volume":"78","author":"J-B Woillard","year":"2014","unstructured":"Woillard J-B, Bader-Meunier B, Salomon R, Ranchin B, Decramer S, Fischbach M, et al. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. Br J Clin Pharmacol. 2014;78:867\u201376. https:\/\/doi.org\/10.1111\/bcp.12392.","journal-title":"Br J Clin Pharmacol"},{"key":"574_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/bios13020206","volume":"13","author":"H Min","year":"2023","unstructured":"Min H, Zhu S, Safi L, Alkourdi M, Nguyen BH, Upadhyay A, et al. Salivary diagnostics in pediatrics and the status of saliva-based biosensors. Biosensors. 2023;13:206. https:\/\/doi.org\/10.3390\/bios13020206.","journal-title":"Biosensors"},{"key":"574_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.18388\/abp.2019_2762","volume":"66","author":"M Wo\u017aniak","year":"2019","unstructured":"Wo\u017aniak M, Paluszkiewicz C, Kwiatek WM. Saliva as a non-invasive material for early diagnosis. Acta Biochim Pol. 2019;66:383\u20138. https:\/\/doi.org\/10.18388\/abp.2019_2762.","journal-title":"Acta Biochim Pol"},{"key":"574_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/ijms17060846","volume":"17","author":"Z Khurshid","year":"2016","unstructured":"Khurshid Z, Zohaib S, Najeeb S, Zafar MS, Slowey PD, Almas K. Human saliva collection devices for proteomics: an update. Int J Mol Sci. 2016;17:846. https:\/\/doi.org\/10.3390\/ijms17060846.","journal-title":"Int J Mol Sci"},{"key":"574_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/bcp.13553","volume":"84","author":"L Hutchinson","year":"2018","unstructured":"Hutchinson L, Sinclair M, Reid B, Burnett K, Callan B. A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants. Br J Clin Pharmacol. 2018;84:1089\u2013108. https:\/\/doi.org\/10.1111\/bcp.13553.","journal-title":"Br J Clin Pharmacol"},{"key":"574_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/bdd.2206","volume":"40","author":"MM Alsmadi","year":"2019","unstructured":"Alsmadi MM, Alfarah MQ, Albderat J, Alsalaita G, AlMardini R, Hamadi S, et al. The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue. Biopharm Drug Dispos. 2019;40:325\u201340. https:\/\/doi.org\/10.1002\/bdd.2206.","journal-title":"Biopharm Drug Dispos"},{"key":"574_CR15","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40261-019-00844-y","volume":"39","author":"E Brooks","year":"2019","unstructured":"Brooks E, Tett SE, Isbel NM, McWhinney B, Staatz CE. Investigation of the association between total and free plasma and saliva mycophenolic acid concentrations following administration of enteric-coated mycophenolate sodium in adult kidney transplant recipients. Clin Drug Investig. 2019;39:1175\u201384. https:\/\/doi.org\/10.1007\/s40261-019-00844-y.","journal-title":"Clin Drug Investig"},{"key":"574_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jsps.2013.02.002","volume":"22","author":"NM Idkaidek","year":"2014","unstructured":"Idkaidek NM. Interplay of biopharmaceutics, biopharmaceutics drug disposition and salivary excretion classification systems. Saudi Pharm J. 2014;22:79\u201381. https:\/\/doi.org\/10.1016\/j.jsps.2013.02.002.","journal-title":"Saudi Pharm J"},{"key":"574_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00228-018-02614-9","volume":"75","author":"PCL Ferreira","year":"2019","unstructured":"Ferreira PCL, Thiesen FV, de Araujo TT, D\u2019\u00c1vila DO, Gadonski G, de Oliveira CSA, et al. Comparison of plasma and oral fluid concentrations of mycophenolic acid and its glucuronide metabolite by LC-MS in kidney transplant patients. Eur J Clin Pharmacol. 2019;75:553\u20139. https:\/\/doi.org\/10.1007\/s00228-018-02614-9.","journal-title":"Eur J Clin Pharmacol"},{"key":"574_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/01.ftd.0000211826.65607.05","volume":"28","author":"AE Mendonza","year":"2006","unstructured":"Mendonza AE, Gohh RY, Akhlaghi F. Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry. Ther Drug Monit. 2006;28:402\u20136. https:\/\/doi.org\/10.1097\/01.ftd.0000211826.65607.05.","journal-title":"Ther Drug Monit"},{"key":"574_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jpba.2009.05.030","volume":"50","author":"B Shen","year":"2009","unstructured":"Shen B, Li S, Zhang Y, Yuan X, Fan Y, Liu Z, et al. Determination of total, free and saliva mycophenolic acid with a LC\u2013MS\/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients. J Pharm Biomed Anal. 2009;50:515\u201321. https:\/\/doi.org\/10.1016\/j.jpba.2009.05.030.","journal-title":"J Pharm Biomed Anal"},{"key":"574_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.chroma.2012.04.008","volume":"1241","author":"MHJ Wiesen","year":"2012","unstructured":"Wiesen MHJ, Farowski F, Feldk\u00f6tter M, Hoppe B, M\u00fclleret C. Liquid chromatography\u2013tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device. J Chromatogr A. 2012;1241:52\u20139. https:\/\/doi.org\/10.1016\/j.chroma.2012.04.008.","journal-title":"J Chromatogr A"},{"key":"574_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/RHU.0000000000000357","volume":"22","author":"JS Hui-Yuen","year":"2016","unstructured":"Hui-Yuen JS, Tran T, Taylor J, Truong K, Li X, Bermudez LM, et al. Use of glucuronidated mycophenolic acid levels for therapeutic monitoring in pediatric lupus nephritis patients. JCR J Clin Rheumatol. 2016;22:75\u20139. https:\/\/doi.org\/10.1097\/RHU.0000000000000357.","journal-title":"JCR J Clin Rheumatol"},{"key":"574_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clinbiochem.2021.11.008","volume":"100","author":"AR Cossart","year":"2022","unstructured":"Cossart AR, Staatz CE, Gorham G, Barraclough KA. Comparison of free plasma versus saliva mycophenolic acid exposure following mycophenolate mofetil administration in adult kidney transplant recipients. Clin Biochem. 2022;100:78\u201381. https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.11.008.","journal-title":"Clin Biochem"},{"key":"574_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s43440-023-00474-4","volume":"75","author":"J Sobiak","year":"2023","unstructured":"Sobiak J, Resztak M, Banasiak J, Zachwieja J, Ostalska-Nowicka D. High-performance liquid chromatography with fluorescence detection for mycophenolic acid determination in saliva samples. Pharmacol Rep. 2023;75:726\u201336. https:\/\/doi.org\/10.1007\/s43440-023-00474-4.","journal-title":"Pharmacol Rep"},{"key":"574_CR24","unstructured":"European Medicine Agency. ICH guideline M10 on bioanalytical method validation and study sample analysis. 2023. https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalyticalmethod-validation-scientific-guideline. Date of entry: January 2023."},{"key":"574_CR25","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.4155\/bio-2017-0214","volume":"9","author":"W Zhou","year":"2017","unstructured":"Zhou W, Yang S, Wang PG. Matrix effects and application of matrix effect factor. Bioanalysis. 2017;9:1839\u201344. https:\/\/doi.org\/10.4155\/bio-2017-0214.","journal-title":"Bioanalysis"},{"key":"574_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2023.115448","volume":"687","author":"A Okolie","year":"2024","unstructured":"Okolie A, Nigro MR, Polk S, Stubbs K, Chelliah S, Ohia SE, et al. Development and application of LC-MS\/MS method for the quantification of hydrogen sulfide in the eye. Anal Biochem. 2024;687: 115448. https:\/\/doi.org\/10.1016\/j.ab.2023.115448.","journal-title":"Anal Biochem"},{"key":"574_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11613\/BM.2015.015","volume":"25","author":"D Giavarina","year":"2015","unstructured":"Giavarina D. Understanding Bland Altman analysis. Biochem Med. 2015;25:141\u201351. https:\/\/doi.org\/10.11613\/BM.2015.015.","journal-title":"Biochem Med"},{"key":"574_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.11613\/BM.2011.010","volume":"21","author":"L Bili\u0107-Zulle","year":"2011","unstructured":"Bili\u0107-Zulle L. Comparison of methods: passing and bablok regression. Biochem Med. 2011;21:49\u201352. https:\/\/doi.org\/10.11613\/BM.2011.010.","journal-title":"Biochem Med"},{"key":"574_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2020.122350","volume":"1159","author":"M Abouzid","year":"2020","unstructured":"Abouzid M, Kara\u017aniewicz-\u0141ada M, Pawlak K, Burchardt P, Kruszyna \u0141, G\u0142\u00f3wka F. Measurement of plasma 25-hydroxyvitamin D2, 25-hydroxyvitamin D3 and 3-epi-25-hydroxyvitamin D3 in population of patients with cardiovascular disease by UPLC-MS\/MS method. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1159: 122350. https:\/\/doi.org\/10.1016\/j.jchromb.2020.122350.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"574_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.11613\/BM.2015.018","volume":"25","author":"LAS Nunes","year":"2015","unstructured":"Nunes LAS, Mussavira S, Bindhu OS. Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: a systematic review. Biochem Med. 2015;25:177\u201392. https:\/\/doi.org\/10.11613\/BM.2015.018.","journal-title":"Biochem Med"},{"key":"574_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2001-1326-1-19","volume":"1","author":"R Mohamed","year":"2012","unstructured":"Mohamed R, Campbell J-L, Cooper-White J, Dimeski G, Punyadeera C. The impact of saliva collection and processing methods on CRP, IgE, and Myoglobin immunoassays. Clin Transl Med. 2012;1:19. https:\/\/doi.org\/10.1186\/2001-1326-1-19.","journal-title":"Clin Transl Med"},{"key":"574_CR32","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s40262-015-0269-z","volume":"54","author":"K Vanstraelen","year":"2015","unstructured":"Vanstraelen K, Maertens J, Augustijns P, Lagrou K, de Loor H, Mols R, et al. Investigation of saliva as an alternative to plasma monitoring of voriconazole. Clin Pharmacokinet. 2015;54:1151\u201360. https:\/\/doi.org\/10.1007\/s40262-015-0269-z.","journal-title":"Clin Pharmacokinet"},{"key":"574_CR33","doi-asserted-by":"publisher","first-page":"30112","DOI":"10.3402\/jom.v8.30112","volume":"8","author":"D Belstr\u00f8m","year":"2016","unstructured":"Belstr\u00f8m D, Holmstrup P, Bardow A, Kokaras A, Fiehn NE, Paster BJ. Comparative analysis of bacterial profiles in unstimulated and stimulated saliva samples. J Oral Microbiol. 2016;8:30112. https:\/\/doi.org\/10.3402\/jom.v8.30112.","journal-title":"J Oral Microbiol"},{"key":"574_CR34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1111\/bcp.15105","volume":"88","author":"A Samb","year":"2022","unstructured":"Samb A, Kruizinga M, Tallahi Y, van Esdonk M, van Heel W, Driessen G, et al. Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: a prospective population pharmacokinetic and simulation study. Brit J Clin Pharmacol. 2022;88:1845\u201355. https:\/\/doi.org\/10.1111\/bcp.15105.","journal-title":"Brit J Clin Pharmacol"},{"key":"574_CR35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4155\/bio-2017-0010","volume":"9","author":"M Gr\u00f6schl","year":"2017","unstructured":"Gr\u00f6schl M. Saliva: a reliable sample matrix in bioanalytics. Bioanalysis. 2017;9:655\u201368. https:\/\/doi.org\/10.4155\/bio-2017-0010.","journal-title":"Bioanalysis"}],"updated-by":[{"DOI":"10.1007\/s43440-024-00617-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000}}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00574-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-024-00574-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00574-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T06:05:52Z","timestamp":1719381952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-024-00574-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["574"],"URL":"https:\/\/doi.org\/10.1007\/s43440-024-00574-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s43440-024-00617-1","asserted-by":"object"}]},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"20 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s43440-024-00617-1","URL":"https:\/\/doi.org\/10.1007\/s43440-024-00617-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent to participate was obtained from all parents or guardians of individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"In the studies involving human participants, all procedures were performed following the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethical Committee at Poznan University of Medical Sciences (Decisions No.: 773\/21 of 06.10.2021 and 808\/22 of 06.10.2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}